titax ami trial y. giraud-sauveur on behalf of p.karjalainen, md, phd : principal investigator bcis...
TRANSCRIPT
TITAX AMI Trial
Y. Giraud-Sauveur on behalf of
P.Karjalainen, MD, PhD : Principal Investigator
BCIS 2009 London, UK
A Prospective, Randomized Trial Comparing TITAN-2® Stent and TAXUS-Liberte® Stent in
Acute Myocardial Infarction
24-months Clinical Follow-Up
TITAX AMI trial
P Karjalainen, MD, PhDJuhani Airaksinen, Antti Ylitalo, Matti Niemelä,
Kari Kervinen, Mikko Pietilä, Jussi Sia,
Kai Nyman, Petri Tuomainen, Timo Mäkikallio
for the TITAX AMI Investigators
All investigators state that no relationships
exist related to this presentation
Titanium-NO Mechanisms of Action
Inhibits Platelet Aggregation
Minimizes Fibrin Growth
Reduces Inflammation
Promotes Healing
Multifunctional Anti-restenotic EffectMultifunctional Anti-restenotic Effect
- Stabilizes microtubules to inhibit smooth muscle cell migration and proliferation
- Stable and durable Translute Polymer * Vascular compatible, biocompatible * Controlled and consistent dose release of paclitaxel
Background: TITAX AMI at 1-YearEurointerv 2008;4:234-241
TCT 2007, Late Breaking Trial
Comparison of titanium-nitride-oxide-coated Comparison of titanium-nitride-oxide-coated TITAN-2TITAN-2®®
Stent to the paclitaxel-eluting Stent to the paclitaxel-eluting TAXUS-LiberteTAXUS-Liberte®® stent stent
resulted in:resulted in:
• Comparable clinical outcome at 1-Year
• Secondly, although the overall risk of stent thrombosis although the overall risk of stent thrombosis was low, it concentrated on the use of TAXUS-Libertewas low, it concentrated on the use of TAXUS-Liberte®® stentstent
• In addition, stent thrombosis occurred in 3 patients after premature discontinuation of clopidogrel.
Participating Centers in Finland
Purpose ofthe TITAX AMI trial
Initiated by the investigators
A Prospective, Multi-center, Randomized Trial that
Compares the Implantation of Titanium-Nitride-Oxide
Coated Stents to Paclitaxel-Eluting Stents for Acute
Myocardial Infarction
Finland
Sweden Russia
* Pori
* * Turku
* Oulu
* Kokkola * Kuopio
* Jyväskylä
Norway
Estonia
Inclusion Criteria:
•• Written informed consent
• Age > 18 years
• Patient with symptoms and
signs of myocardial
infarction requiring PCI
Exclusion Criteria:
•• Prior PCI on target vessel
(restenosis)
• Unprotected LM disease
• Ostial lesion
• Contraindication to aspirin,
heparins, clopidogrel,
(allergy / risk for bleeding)
• Life expectancy < 12 months
• Stent length needed > 28 mm
Inclusion / Exclusion
TITAX AMI trial: Study Design425 Patients Presenting Acute
Myocardial Infarction Requiring PCI
Written Informed Consent
Randomization 1:1
TITAN-2® stent (Hexacath)Titanium-Nitride-Oxide Coated StentTitanium-Nitride-Oxide Coated Stent
(TITANOX)(TITANOX) 214 Patients
TAXUS-Liberte® stent (Boston)Paclitaxel-Eluting Stent
(PES) 211 Patients
Primary Endpoint: MACE at 1 Year
Independent Endpoint CommitteeIndependent Endpoint Committee
TITAX AMI trial
•• Primary Endpoint
MACE at 12- months including• Myocardial infarction• TLR (PCI or CABG)• Cardiac death
•• Secondary Endpoints
- Composite of cardiac death or recurrent MI - All cause death - Stent Thrombosis
Definition of Stent Thrombosis The Academic Research Consortium (ARC)
Definite: - Acute coronary syndrome and angiographic (or autopsy) confirmation of stent thrombosis
Probable:- Any unexplained death within the first 30 days- Target vessel related AMI
Possible:- Any unexplained death from 30 days after PCI
Baseline Patient Characteristics TITAN-2®
(N=214)
TAXUS-L*®
(N=211)
P value
Age (mean ± SD) 64 ± 11 64 ± 11 0.72
Male sex, n (%) 162 (76) 157 (74) 0.82
Diabetes, n (%) 48 (22) 33 (16) 0.08
History of smoking, n (%) 113 (53) 97 (46) 0.18
Hyperlipidemia, n (%) 141 (66) 151 (72) 0.21
Previous PCI, n (%) 22 (10) 10 (5) 0.04
Previous CABG, n (%) 16 (7) 13 (6) 0.70
Acute STEMI, n (%) 83 (39) 97 (46) 0.14
Thrombolysis, n (%) 26 (12) 40 (19) 0.06
GP IIb/IIIa Inhibitors, n (%) 116 (54) 96 (45) 0.81
* L= Liberte* L= Liberte
Lesion Characteristics TITAN-2®
(N=214)
TAXUS-L*®
(N=211)
P value
Infarct-related Vessel, n (%)
LAD 98 (46) 91 (43) 0.63
LCX 44 (21) 50 (24) 0.48
RCA 62 (29) 60 (28) 0.92
Left Main 0 (0) 1 (0.5) 0.50
Bypass Graft (venous) 10 (5) 9 (4) 0.84
Complex Lesions, n (%)
B1 / B2 147 (69) 138 (65) 0.54
C 35 (16) 24 (11) 0.16
* L= Liberte* L= Liberte
Procedural and Lesion Characteristics TITAN-2®
(N=214)
TAXUS-L*®
(N=211)
P Value
RVD, (mm) 3.16 ± 0.45 3.11 ± 0.50 0.35
Lesion length, (mm) 13.6 ± 5.6 13.2 ± 6.4 0.47
Stent diameter, (mm) 3.16 ± 0.42 3.11 ± 0.45 0.19
Stent length, (mm) 17.4 ± 4.5 17.7 ± 5.3 0.48
Total stent length, (mm) 18.5 ± 6.4 19.2 ± 7.2 0.26
No of stents per lesion, n (%) 1.1 ± 0.3 1.1 ± 0.4 0.24
Acute Procedural Success, n (%) 213 (99.5) 207 (98.1) 0.21
Multivessel PCI, n (%) 30 (14) 19 (9) 0.13
* L= Liberte* L= Liberte
Antiplatelet Agent Utilization
TITAN-2®
(N=214)
TAXUS-L*®
(N=211)
P
value
Aspirin
- At 6 months 100% 98.6% ns
- At 12 months 100% 98.6% ns
Clopidogrel
- At 6 months 89.3% 98.1% < 0.05
- At 12 months 31.3% 65.4% < 0.001
Mean duration, (months) 7.6 10.1 < 0.001
* L= Liberte* L= Liberte
Extended clopidogrel treatmentsExtended clopidogrel treatmentsbeyond 12 months were discouragedbeyond 12 months were discouraged
Patient Flow - ClinicalRandomized
(N=425)
TITAN-2® stent(N=214/214)
TAXUS-Liberte® stent (N=211/211)
1-Year follow-up1-Year follow-up(N=425/425; 100%)(N=425/425; 100%)
TITAN-2® stent(N=214/214)
24 months follow-up24 months follow-up(N=424/425; 99.8%)(N=424/425; 99.8%)
TAXUS-Liberte® stent (N=210/211)
1 = Lost to f/u1 = Lost to f/uLost to f/u = 0Lost to f/u = 0
TITAX AMI trialMACE at 12, 18 and 24 months
10,3
12,8
000
5
10
15
20
25
12 18 24
TITAN-2
TAXUS-Liberte
%
p = 0.5
TITAX AMI trialMACE at 12, 18 and 24 months
10,3
12,8
17,1
10,3
0
5
10
15
20
25
12 18 24
TITAN-2
TAXUS-Liberte
%
p = 0.04
p = 0.5
TITAX AMI trialMACE at 12, 18 and 24 months
10,311,2
12,8
17,1
21,3
10,3
0
5
10
15
20
25
12 18 24
TITAN-2
TAXUS-Liberte
%
p = 0.04
p = 0.5
p = 0.006
TITAX AMI trialMI at 12, 18 and 24 months
4,25,1
8,1
11,8
15,6
4,2
0
5
10
15
20
25
12 18 24
TITAN-2
TAXUS-Liberte
%
p = 0.004
NS
p < 0.001
TITAX AMI trialCardiac Death at 12, 18 and 24 months
0,5 0,91,9
3,84,7
0,5
0
5
10
15
20
25
12 18 24
TITAN-2
TAXUS-Liberte
%
p = 0.02
NS
p = 0.02
TITAX AMI trialTLR at 12, 18 and 24 months
9,3 9,3
7,1
9,5 109,3
0
5
10
15
20
25
12 18 24
TITAN-2
TAXUS-Liberte
%
NSNSNS
TITAX AMI trialDefinite Stent Thrombosis at
12, 18 and 24 months
0,5 0,5
3,3
5,2 5,7
0,5
0
5
10
15
20
25
12 18 24
TITAN-2
TAXUS-Liberte
%
p = 0.003
p = 0.03
p = 0.001
TITAX AMI trialMI or Cardiac Death at 12, 18 and 24
months
4,25,1
8,5
13,7
18,5
4,2
0
5
10
15
20
25
12 18 24
TITAN-2
TAXUS-Liberte
%
p = 0.001
p = 0.08
p < 0.001
TITAX AMI trial:Conclusions (24 months follow-up)
• Late follow up (12 to 24 months) after the clopidogrel discontinuation showed higher rates of:- Myocardial Infarction- Cardiac Death- MACE
with the use of TAXUS-Liberte® stent
• Secondly, the incidence of Stent Thrombosis (ARC definition) was significantly higher in the TAXUS-Liberte® stent group
• TITAN-2® stent: non-inferior 24-months rate of TLR
TITAX AMI trial
Possible limitations:Possible limitations:
• Small sample size (425 patients)
• Thrombolysis therapy not excluded
Strengths of the study:
• Initiated by the investigators, no sponsors
• Prospective, randomized, multicenter study
• Primary clinical end point
• New ARC definition of stent thrombosis